Enveda Biosciences

Enveda Biosciences takes a distinctive angle on AI drug discovery: mining the chemistry of nature. Plants and other organisms produce an enormous, largely uncharacterized universe of small molecules; Enveda applies machine learning to mass-spectrometry and metabolomics data to identify and decode these natural compounds and turn promising ones into drug candidates. Having characterized more than a million compounds and raised significant funding, including a Series C of roughly 130 million dollars, the company has moved a lead program into Phase 1 for atopic dermatitis, with a pipeline of additional candidates behind it. Enveda shows that AI-for-discovery is not only about designing molecules from scratch — it can also be about reading and exploiting the molecules nature already made. As with all clinical-stage biotech, early trials are the first real test, not the final word.